VacZine Analytics  
MarketVIEW: Enterovirus-71 vaccines

Published: February 2012

Enterovirus-71 (EV-71), a small member of the picornaviridae virus family, is a major causative agent of “hand foot and mouth” HFMD disease in South East Asia. In some countries EV-71 related HFMD outbreaks appear to be increasing in magnitude and frequency and are responsible for significant childhood mortality (905 deaths in China 2010) (est CFR 0.03%). Like Japanese encephalitis (JEV), an inactivated EV-71 vaccine has high likelihood of region specific national adoption in the SE Asia. Four such vaccines appear to be in late stage clinical trials in China with the first launch expected 2014.

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of EV-71 vaccines to 2030 in the SE Asia region. The product examines different scenarios of sucessive country based vaccine deployment in the <1 yrs and 1-5 yrs age groups. Detailed coverage of latest EV-71 epidemiology (outbreaks) is included, also a focus on development history/approaches to date and coverage of latest cost effectiveness issues. Expected revenues per competitor (public) sector are included for the late stage Phase III programs operated by Sinovac and China National Biotech Group (Beijing Vigoo Biological Co Ltd).

This product is an ideal starting point for any manufacturer wishing to assess this emerging market in the SE Asia region.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV032 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains